CIK 0000771856 · Non-accelerated filer<br>Smaller reporting company
CHAMPIONS ONCOLOGY, INC.
Sign in to watch- Ticker
- CSBR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 521401755
- Phone
- 410-369-0365
- Business address
- 855 N. WOLFE STREET, SUITE 619, BALTIMORE, MD, 21205
- Former names
- CHAMPIONS BIOTECHNOLOGY, INC., CHAMPIONS SPORTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-05 | SIDRANSKY DAVID Director | Grant or award · Option to purchase Common Stock | +31,216 | $4.76 | $149K | 31,216 |
| 2026-11-05 | Mendelson Daniel Newman Director | Grant or award · Option to purchase Common Stock | +20,291 | $4.76 | $97K | 20,291 |
| 2026-11-05 | TOBIN SCOTT R Director | Grant or award · Option to purchase Common Stock | +37,460 | $4.76 | $178K | 37,460 |
| 2026-11-05 | ACKERMAN JOEL Director | Grant or award · Option to purchase Common Stock | +31,216 | $4.76 | $149K | 31,216 |
| 2026-10-15 | ACKERMAN JOEL Director | Option exercise | +69,794 | $1.60 | $112K | 1,126,333 |
| 2026-10-15 | ACKERMAN JOEL Director | Option exercise · Option to purchase Common Stock | −69,794 | $1.60 | $112K | 0 |
| 2025-11-05 | Breitfeld Philip P. Director | Grant or award · Option to purchase Common Stock | +13,790 | $6.80 | $94K | 13,790 |
| 2025-11-05 | SIDRANSKY DAVID Director | Grant or award · Option to purchase Common Stock | +21,216 | $6.80 | $144K | 21,216 |
| 2025-11-05 | Mendelson Daniel Newman Director | Grant or award · Option to purchase Common Stock | +13,790 | $6.80 | $94K | 13,790 |
| 2025-11-05 | TOBIN SCOTT R Director | Grant or award · Option to purchase Common Stock | +25,460 | $6.80 | $173K | 25,460 |
| 2025-11-05 | ACKERMAN JOEL Director | Grant or award · Option to purchase Common Stock | +21,216 | $6.80 | $144K | 21,216 |
| 2025-10-30 | ACKERMAN JOEL Director | Option exercise | +94,405 | $2.10 | $198K | 1,056,539 |
| 2025-10-30 | ACKERMAN JOEL Director | Option exercise · Option to purchase Common Stock | −94,405 | $2.10 | $198K | 0 |
| 2025-07-16 | Brainin Robert Lawrence CEO | Grant or award · Option to purchase Common Stock | +225,000 | $7.80 | $1.8M | 299,163 |
| 2025-07-16 | Brainin Robert Lawrence CEO | Grant or award · Option to purchase Common Stock | +62,500 | $7.80 | $488K | 361,663 |
| 2025-07-16 | Brainin Robert Lawrence CEO | Grant or award · Option to purchase Common Stock | +62,500 | $7.80 | $488K | 424,163 |
| 2025-07-16 | Brainin Robert Lawrence CEO | Grant or award · Option to purchase Common Stock | +150,000 | $7.80 | $1.2M | 574,163 |
| 2025-07-16 | Brainin Robert Lawrence CEO | Grant or award · Option to purchase Common Stock | +100,000 | $7.80 | $780K | 674,163 |
| 2025-07-16 | Brainin Robert Lawrence CEO | Grant or award · Option to purchase Common Stock | +100,000 | $7.80 | $780K | 774,163 |
| 2025-03-25 | Breitfeld Philip P. Director | Other disposition | −4,150 | 5,717 |
Page 1 of 20 · 398 trades